2016
DOI: 10.1111/ane.12699
|View full text |Cite
|
Sign up to set email alerts
|

JCV serology in time: 3 years of follow-up

Abstract: JCV-negative patients and JCV-positive patients with antibody levels below or equal to 0.9 both have a low risk of surpassing the 1.5 threshold.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 25 publications
1
8
0
Order By: Relevance
“…The frequency of serum testing clearly influences the probability of a serostatus change when examining JCV antibody status-with higher frequency of seroconversion (changing from a negative to positive result) reported in more recent studies when patients are tested more often [46,47]. The optimal frequency of testing is not well established.…”
Section: Jcv Antibody Testingmentioning
confidence: 99%
“…The frequency of serum testing clearly influences the probability of a serostatus change when examining JCV antibody status-with higher frequency of seroconversion (changing from a negative to positive result) reported in more recent studies when patients are tested more often [46,47]. The optimal frequency of testing is not well established.…”
Section: Jcv Antibody Testingmentioning
confidence: 99%
“…We suggest that FTY should be used with caution in patients with JCV‐seropositive or high anti‐JCV antibody index (>1.5) 72, 73. Patients who develop new neurological symptoms suggestive of PML should be urgently evaluated at very early stage and have expeditious MRI and JCV‐polymerase chain reaction analysis.…”
Section: Fingolimod and Progressive Multifocal Leukoencephalopathymentioning
confidence: 99%
“…The existing data on the seroprevalence of anti-JCV Ab and anti-JCV AI levels in the population of MS patients mainly originate from trials in which PwMS were receiving disease-modifying therapy (DMT), especially natalizumab [ 23 , 24 , 25 , 26 , 27 , 28 ]. The vital characteristic of our study cohort comprising MS patients is the fact that nearly one half of them were treatment naïve, while the remaining study population was receiving DMT with the use of immunomodulatory or immunosuppressive agents; the proportion of patients treated with natalizumab was minimal.…”
Section: Discussionmentioning
confidence: 99%